Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Gemma Figtree: Using Ultra-Low Troponin Levels to Guide Coronary CT Scans
Gemma Figtree/LinkedIn
Aug 4, 2026, 07:07

Gemma Figtree: Using Ultra-Low Troponin Levels to Guide Coronary CT Scans

Gemma Figtree, Professor and Cardiologist at University of Sydney and Royal North Shore Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Nature Cardiovascular Research, adding:

“We use troponin to diagnose heart attacks. Sina Fathieh and our team Michael Patrick Gray Stuart Grieve Louise Cullen Stephen Nicholls asked whether it could help us prevent them.

Sina’s paper is out today in Nature Cardiovascular Research. In 1,613 BioHEART participants, a high-sensitivity troponin I of just 2.3 ng/L — about a twelfth of the level we use to call an infarct — flagged people carrying clinically actionable coronary disease on CT.

Two results I didn’t expect Nicholas Mills Roxana Mehran Deepak L. Bhatt, Mike Ryan

It worked best in the people our risk calculators miss. In those with none of the four standard modifiable risk factors, a troponin above 2.3 carried roughly four-fold odds of actionable disease.

And Sina’s insight to normalise troponin to age and renal function plus or minus left ventricular mass lifted discrimination from 0.64 to 0.81 — with a mechanism attached.

The association was strongest for plaque in proximal segments, where more myocardium sits downstream. Consistent with micro-injury arising from the plaque itself.

Used as a triage step before imaging, it nearly halved the scans needed to find one actionable case, and cut them from 7.2 to 3 in the SMuRF-less group.

What I want to say about the person rather than the paper: Sina built the Bayesian error-in-variables framework that makes these numbers trustworthy at the very low troponin concentrations where assays get noisy.

That was his idea, and it is the reason a reviewer could not dismiss the finding as measurement artefact. It is careful, unglamorous, genuinely difficult work.

We also benefited from collaboration of a terrifically diverse team of clinicians, fundamental researchers, and omics experts, as well as industry partners.

Retrospective, and prospective testing has to come next. But this is what an early-career clinician researcher asking a good question looks like.

Assay consumables were supported by Abbott Diagnostics; declared in the paper.”

Title: Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease

Authors: Sina Fathieh, Michael P. Gray, Owen Tang, Katharine A. Bate, Stephen T. Vernon, Elijah Genetzakis, Soloman Saleh, Gillian Murtagh, Jean Y. Yang, Collin Tran, David R. Sullivan, Paul Bonnitcha, David S. Celermajer, Louise Cullen, Ravinay Bhindi, Jamil Mayet, Stephen J. Nicholls, Stuart M. Grieve and Gemma A. Figtree

Gemma Figtree: Using Ultra-Low Troponin Levels to Guide Coronary CT Scans

Stay updated with Hemostasis Today.

bleeding disorders Blood Cardiology Collin Tran David R. Sullivan David S. Celermajer Elijah Genetzakis Gemma A Figtree Gemma Figtree Gene therapy Gillian Murtagh Headlines Health Hematology Hemophilia Hemostasis Hemostasis Today Jamil Mayet Jean Y. Yang Katharine A. Bate Louise Cullen Medicine Michael P. Gray Owen Tang Paul Bonnitcha Ravinay Bhindi Sina Fathieh Soloman Saleh Stephen J Nicholls Stephen T. Vernon Stuart M. Grieve thrombosis
NewsFeed